<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220107053654N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-07-14</date_registration>
      <primary_sponsor>Oroumia University of Medical Sciences</primary_sponsor>
      <public_title>Effect of Lavender Oil on The Anxiety, Heart Rate And Blood Pressure of Children</public_title>
      <acronym></acronym>
      <scientific_title>Investigation of The Effect of Lavender Oil Inhalation on Anxiety, Heart Rate And Blood Pressure of Children's Dental Treatment</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-10-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>46</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/90006</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In order to control for the confounding effect of gender on anxiety levels, stratified randomization will be used. For this purpose, participants will first be divided into two strata (girls and boys) based on gender. To allocate participants to the intervention and control groups, a random sequence will be generated using SPSS software, taking into account random blocks of a size of 4. The unit of randomization will be the individual participant. To ensure allocation concealment, the generated sequence will not be available to the main investigator, and sealed envelopes will be used so that the allocation of each individual to the groups will be performed by a person who does not play a role in the screening and enrollment process of the participants. Finally, 12 girls and 11 boys will be entered into the study in each group, Blinding description: The researcher and the treating dentist will not be aware of the patient’s exposure to the aroma. The implementation of the intervention will be performed by another student who will have no role in data collection or data analysis. Following completion of the intervention, the room will be ventilated in order to maintain the blinding conditions, and subsequently the dental treatment will be initiated. In the control group, all procedures will be performed similarly, with the difference that sterile distilled water will be used on the gauze instead of lavender essence.</study_design>
      <phase>3</phase>
      <hc_freetext>local anesthetic injection.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Receives inhalational lavender oil aroma (Essential oil will be obtained by hydrodistillation of dried plant parts and subsequently purifies with anhydrous sodium thiosulfate; Prepared at the Faculty of Pharmacology, Urmia University of Medical Sciences) 60 minutes before the start of dental procedures (anesthetic injection); 0.5 mL of the oil is dripped onto a 7.5 × 7.5 cm gauze and placed 20 cm from the child’s nose for 15 minutes. Intervention 2: Control group: Distilled water was administered by inhalation 60 minutes before the start of the dental procedure (local anesthetic injection). A total of 0.5 mL of distilled water was applied to a 7.5 × 7.5 cm gauze pad, which was placed 20 cm from the child's nose for 15 minutes.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Its publication schedule has not yet been determined.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Maryam Khosrozadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Mohtasham Street, Molavi 2, Behdari District Urmia, West Azerbaijan Province</address>
        <city>Urmia</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5714783734</zip>
        <telephone>+98 44 3365 0729</telephone>
        <email>khosrozadeh.mm@gmail.com</email>
        <affiliation>Oroumia University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Maryam Khosrozadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Mohtasham Street, Molavi 2, Behdari District Urmia, West Azerbaijan Province</address>
        <city>Urmia</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5714783734</zip>
        <telephone>+98 44 3365 0729</telephone>
        <email>khosrozadeh.mm@gmail.com</email>
        <affiliation>Oroumia University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>children with healthy systemic condition
Age of patients between 7 and 9 years
Children requiring restorative treatment of the mandibular permanent first molar on one side</inclusion_criteria>
      <agemin>7 years</agemin>
      <agemax>9 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients with prior dental treatment
Children with symptoms of dental pain</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>T41.3X5</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Adverse effect of local anesthetics</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Receives inhalational lavender oil aroma (Essential oil will be obtained by hydrodistillation of dried plant parts and subsequently purifies with anhydrous sodium thiosulfate; Prepared at the Faculty of Pharmacology, Urmia University of Medical Sciences) 60 minutes before the start of dental procedures (anesthetic injection); 0.5 mL of the oil is dripped onto a 7.5 × 7.5 cm gauze and placed 20 cm from the child’s nose for 15 minutes.</i_keyword>
      <i_keyword>Control group: Distilled water was administered by inhalation 60 minutes before the start of the dental procedure (local anesthetic injection). A total of 0.5 mL of distilled water was applied to a 7.5 × 7.5 cm gauze pad, which was placed 20 cm from the child's nose for 15 minutes.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Anxiety. Timepoint: During local anesthetic administration; 60 minutes after the intervention. Method of measurement: Facial rating scale.</prim_outcome>
      <prim_outcome>Heart rate. Timepoint: Once before receiving the inhaled aroma; and again 1 minute after completion of the local anesthetic injection. Method of measurement: Digital sphygmomanometer.</prim_outcome>
      <prim_outcome>Systolic blood pressure. Timepoint: Once before receiving the inhaled aroma; and again 1 minute after completion of the local anesthetic injection. Method of measurement: Digital sphygmomanometer.</prim_outcome>
      <prim_outcome>Diastolic blood pressure. Timepoint: Once before receiving the inhaled aroma; and again 1 minute after completion of the local anesthetic injection. Method of measurement: Digital sphygmomanometer.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Oroumia University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-10-22</approval_date>
        <contact_name>Research Ethics Committees of Urmia University of Medical Sciences</contact_name>
        <contact_address>Urmia University of Medical Sciences, Emergency Alley, Resalat St., Urmia, Iran Urmia West Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
